Jazz Pharmaceuticals PLC at Wells Fargo Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : So I have like 15 questions on zani. So let's just start with zani first, right? And then probably we'll get (inaudible) and the results. So I think you talked about breast cancer. And I mean, I really kind of understand that ENHERTU is going to be a big product in breast cancer. And you are going after -- your strategy is to go after ENHERTU there. So can you talk a little bit about what you have seen so far in the clinical trial settings where -- which gives you confidence that it could work in that particular setting? And your strategy seems to be going after and ENHERTU. So just talk a little bit about that. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 04, 2024 / 2:15PM, JAZZ.OQ - Jazz Pharmaceuticals PLC at Wells Fargo Healthcare Conference

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. And then theoretically, patients who have hadn't ENHERTU before, HERCEPTIN should not be very effective on those questions because they already had that?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it.

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Yes, lets' talk about it now.

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. So this is very fascinating actually. So -- and then like I want to get Abizer as well in this mix. So when you talk to experts and like again, Rob talked about unmet need here. I mean, what do you hear when you talk to -- when you go into oncology field?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. That's super helpful. So look, one last question on this. So with the BTC approval, do you think there is room for some kind of NCCN guideline that allows for GEA before approval as well? Like is a possibility there?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. And then, I mean, your data are not that far either, right? Second quarter '25, you'll start to -- you'll have data for GEA?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. So I mean, just talk to us in terms of like what is the bar for success there? And then there are questions around like how should we think about like baseline PD-L1 status and then how the --

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. This is helpful. And then maybe from the commercial side, I mean, can you talk a little bit about the overlap, the work you can do with your existing oncology franchise which could help you launch zani eventually?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : That's awesome. So Phil, can I ask you a tough question. It has been two quarters for you.

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : No, I mean -- so I think what I want to ask is that how has been your experience so far, I mean, in the last few quarters? And then obviously, there was a decision made to take away the '25 guidance. But what I really want to ask is that you have this oncology side and you have this -- the legacy business, which -- or legacy pipeline as well. So how do you balance that? Because you have a lot of opportunity in the oncology side as well. So how you are thinking about the margins and the thought process around expenses and all that?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : That completely makes sense. I mean, the follow-up to that is that you have -- you're in kind of three different areas. You have a narcolepsy franchise, you have a kind of neuro franchise with epilepsy and all and then you have an oncology franchise. So one, when you're thinking about new assets, are you going to be in your wheelhouse, so to speak, versus expanding beyond that? And then how do you enhance leverage in these three areas where you are in?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. And then, I mean, if I think about, I mean, types of business development opportunities that are out there, I mean, value is created sometimes when you can actually add to R&D rather than actually buy revenues. That's what you're doing with zani as well. So I mean, what is your thought process on -- in terms of like when you look at the asset, what Jazz needs right now. Like when you think about asset to need, I mean, what do you think?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. This makes sense. So we got to 26 minutes without talking about narcolepsy. So next year, the target is to do it without talking about that. But let's just -- this year, let's just talk about that. So you did talk about narcolepsy in the sense on the earnings call that it is kind of -- the growth will probably come from IH. Can you talk a little bit more about how you see the market now? And then I think people do -- investors do -- because your guidance also was until 2025 when it was there. People do worry about '26 and beyond that, I mean, how this business is going to shape up or going to be -- what is the outlook there. So how do you think about next few years? And then qualitatively, how should we think about this?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. And you had a court win as well against the competitor there, especially for IH. So can you talk about the significance of that? Because it seems like they're still learning the trial, but basically, you can block them from launching in IH at this point, right? I mean, is that what it means?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. Super helpful. One question I wanted to ask you, ask about the commercial side of it, but Zepzelca and Rylaze. So how do you think about these franchisees in near to medium term? And what is the significance -- like how significant do you think Zepzelca plus Tecentriq trial could be for investors to understand?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Got it. That makes sense. So maybe in the last minute, I think this is the last question for you, Phil. Fast forward one year, September 2025. You are here. I hope you are here. And I'm asking you, like what would you -- what -- at that point, what would make you look back at the year and say it was a good year?

Question: Mohit Bansal - Wells Fargo Securities, LLC - Analyst : Awesome. On that high note, thank you very much.